Search

Your search keyword '"Ken Ogasawara"' showing total 18 results

Search Constraints

Start Over You searched for: Author "Ken Ogasawara" Remove constraint Author: "Ken Ogasawara" Publisher elsevier bv Remove constraint Publisher: elsevier bv
18 results on '"Ken Ogasawara"'

Search Results

1. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

2. Primary Analysis (PA) Results from the Randomized, Phase 3 TRANSFORM Study of Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)

Catalog

Books, media, physical & digital resources

3. Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

4. Two-Year (yr) Follow-up (FU) of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

5. Experience of Prior Anti-CD19 Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Non-Hodgkin Lymphoma (B-NHL) Receiving Lisocabtagene Maraleucel (liso-cel), an Investigational Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Product

6. Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed/Refractory (R/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT

8. Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease

9. Decreased CYP3A4 activity and protein in nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH)

10. Vascular Ehlers-Danlos syndrome

11. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease

12. A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease

13. Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese

14. Increased level of advanced oxidation protein products in patients with coronary artery disease

15. Erratum to 'A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease' [Atherosclerosis 2004;174(2):349–356]

16. Beta-thromboglobulin release within coronary circulation — a potential role of platelets in ergonovine-induced coronary vasospasm

17. Effect of nicorandil on coronary spasm

18. Angina preceding myocardial infarction and residual coronary narrowing after intracoronary thrombolysis